In that study, alectinib 600 mg orally twice per day was compared to crizotinib 250 mg orally twice per day in patients with ALK mutation positive advanced disease of non-small cell lung cancer, with significantly better progression-free survival at 12 months with alectinib (68.4%) than with crizotinib (48.7%) [8]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.